Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US5994319A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Apr 14, 1997 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Apr 14, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Minoxidil has been shown to stimulate hair growth or inhibit the loss of hair in a number of patients beginning to develop androgenic alopecia. The mechanism by which minoxidil (2,4-pyrimidinediamine, 6-(1-piperidinyl)-3-oxide) alters the hair growth cycle is uncertain, but is thought to act by increasing vascular circulation to the hair follicle. Inhibitors of steroid metabolism, particularly those that inhibit the conversion of testosterone to dihydrotestosterone, have shown effects on hair cycles, including inhibition of hair loss. One class of enzymes targeted by these inhibitors are the steroid 5-alpha reductases. Minoxidil used in conjunction with effectors of steroid metabolism, leads to enhanced hair growth and decreased rates of hair loss. This specification relates to the use of antisense oligonucleotides targeting 5-alpha reductases used in conjunction with other hair growth enhancers and/or hair loss inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.